Phase I evaluation of vindesine in children: A southwest oncology group pilot study

Publisher Website
Google Scholar
Abstract
Twenty‐one children (19 with leukemia) were given 34 courses of vindesine on a weekly or twice‐weekly schedule in escalating doses. Thirty‐three courses were fully or partially evaluable for response and/or toxicity. Granulocyto‐penia was the dose‐limiting toxicity. Transient jaw, neck, or bone pain was common after each dose. Motor weakness, paresthesias, and constipation were neither frequent nor severe. In this Phase I study, vindesine had some antileu‐kemia activity in children previously treated with vincristine and other drugs. Phase II studies are warranted and a starting dose of 1.85 mg/m2 twice weekly appears tolerable.

This publication has 2 references indexed in Scilit: